... KALAMAZOO Mich. May 2 /- Stryker Corporat...The warning letter concerns observations made during an inspection tha...Several corrective actions and changes to processes put in place bySt... We take this matter very seriously will continue to cooperate fully...

KALAMAZOO, Mich., May 2 /PRNewswire-FirstCall/ -- Stryker Corporation
(NYSE: SYK) announced today that its Biotech division has received a
warning letter from the U. S. Food and Drug Administration (FDA) related to
quality systems and compliance issues at its Hopkinton, Massachusetts
location.

The warning letter concerns observations made during an inspection that
was initiated in September 2007. The letter primarily cites issues relating
to Stryker Biotech's handling of a past clinical study, its quality system
including medical device reporting procedures, and the integrity of
hospital Institutional Review Board (IRB) documentation used to approve
implantation of Humanitarian Use Devices.

Several corrective actions and changes to processes put in place by
Stryker Biotech were noted in the letter and future improvements are
forthcoming as the division continues to work with FDA. No products have
been recalled as a result of this warning letter. In addition, there were
no observations related to any ongoing clinical trials or clinical trial
IRBs.

"We take this matter very seriously, will continue to cooperate fully
with FDA, and have initiated significant measures to address FDA's
concerns," said Stephen P. MacMillan, President and Chief Executive Officer
of Stryker Corporation.

In addition to specific corrective actions implemented at the Biotech
division, Stryker recently launched a company-wide Quality Action Plan
aimed at strengthening corporate-level oversight and at institutionalizing
a more consistent implementation of best practices for meeting FDA
requirements.

As part of its Quality Action Plan Stryker has:

-- Strengthened roles and responsibilities to increase accountability for

quality

-- Established new company-wide standard operating procedures for quality

processes that will be implemented consistently at each division

-- Reorganized quality functions at the plant, division and corporate

levels and increased third-party monitoring at all levels

-- Tied a significant portion of senior management's compensation to

meeting quality improvement measures

"We are committed to strengthening our quality systems to fully meet
all FDA requirements. While we have made progress in fulfilling this
commitment, we still have more work to do" MacMillan added.

Forward-Looking Statements

This press release contains information that includes or is based on
forward-looking statements within the meaning of the federal securities law
that are subject to various risks and uncertainties that could cause the
Company's actual results to differ materially from those expressed or
implied in such statements. Such factors include, but are not limited to:
pricing pressures generally, including cost-containment measures that could
adversely affect the price of or demand for the Company's products;
regulatory actions; unanticipated issues arising in connection with
clinical studies and otherwise that affect U.S. Food and Drug
Administration approval of new products; changes in reimbursement levels
from third-party payors; a significant increase in product liability
claims; changes in economic conditions that adversely affect the level of
demand for the Company's products; changes in foreign exchange markets;
changes in financial markets; and changes in the competitive environment.
Additional information concerning these and other factors is contained in
the Company's filings with the U.S. Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.

Stryker Corporation is one of the world's leading medical technology
companies with the most broadly based range of products in orthopaedics and
a significant presence in other medical specialties. Stryker works with
respected medical professionals to help people lead more active and more
satisfying lives. The Company's products include implants used in joint
replacement, trauma, craniomaxillofacial and spinal surgeries; biologics;
surgical, neurologic, ear, nose & throat and interventional pain equipment;
and endoscopic, surgical navigation, communications and digital imaging
systems; as well as patient handling and emergency medical equipment. For
more information about Stryker, please visit the company web site at
http://www.stryker.com .

(Date:12/9/2016)... 2016 Research and Markets has announced ... report to their offering. ... The report forecasts the global optical transceiver market to ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...

(Date:12/9/2016)... Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged ... rare diseases, today announced that senior management will participate in a ... at the InterContinental Barclay Hotel in New York City ... About aTyr Pharma ... aTyr Pharma is engaged in the discovery ...

(Date:12/9/2016)... 2016 Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...

(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...

(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...

(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...